Johnson & Johnson, United States
Disclosure information not submitted.
Brain-penetrant calcium channel blockers for psychiatric use: revisiting the evidence for benefit
Tuesday, August 27, 20242:00 PM – 2:15 PM CEST
The use of brain-penetrant calcium channel blockers (BP-CCBs) and risk of suicidality and hospitalization among patients with neuropsychiatric disorders: a retrospective comparative cohort study
Tuesday, August 27, 20242:15 PM – 2:30 PM CEST
